The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 08, 2025
Filed:
Nov. 10, 2020
Applicant:
Enanta Pharmaceuticals, Inc., Watertown, MA (US);
Inventors:
Brian C. Shook, Holliston, MA (US);
In Jong Kim, Lexington, MA (US);
Thomas P. Blaisdell, Watertown, MA (US);
Jianming Yu, Plainsboro, NJ (US);
Joseph Panarese, Newton, MA (US);
Kai Lin, Belmont, MA (US);
Michael H. J. Rhodin, Stow, MA (US);
Nicole V. McAllister, Groton, MA (US);
Yat Sun Or, Waltham, MA (US);
Assignee:
Enanta Pharmaceuticals, Inc., Watertown, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5513 (2006.01); A61K 31/4439 (2006.01); A61K 31/7056 (2006.01); A61K 39/395 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); C07D 213/12 (2006.01); C07D 213/14 (2006.01); C07D 217/12 (2006.01); C07D 217/14 (2006.01); C07D 243/24 (2006.01); C07D 403/12 (2006.01); C07D 491/04 (2006.01); C07D 498/08 (2006.01); C07K 16/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5513 (2013.01); A61K 31/4439 (2013.01); A61K 31/7056 (2013.01); A61K 39/395 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); C07D 213/12 (2013.01); C07D 213/14 (2013.01); C07D 217/12 (2013.01); C07D 217/14 (2013.01); C07D 243/24 (2013.01); C07D 403/12 (2013.01); C07D 491/04 (2013.01); C07D 498/08 (2013.01); C07K 16/1027 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.